As 2013 winds down, we asked several venture capital investors to reflect on the past year and give us their outlook for 2014. The latest in our series is John Neis, managing director, Venture Investors.
Mr. Neis speaks about the challenge of putting together syndicates for life-sciences investment, how returns are improving and the need for biotech companies to perform after going public.
Image: Venture Investors
